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We conducted a prospective pilot study of the serolog-
ic responses to overlapping recombinant fragments of the
Pneumocystis jirovecii major surface glycoprotein (Msg) in
HIV-infected patients with pneumonia due to P. jirovecii
and other causes. Similar baseline geometric mean anti-
body levels to the fragments measured by an ELISA were
found in both groups. Serum antibodies to MsgC in P.
jirovecii patients rose to a peak level 3–4 weeks (p<0.001)
after recovery from pneumocystosis; baseline CD4+ count
>50 cells/µL and first episode of pneumocystosis were the
principal host factors associated with this rise (both
p<0.001). Thus, MsgC shows promise as a serologic
reagent and should be tested further in clinical and epi-
demiologic studies.
Pneumocystis jirovecii, formerly known asPneumocystis carinii special form hominis (1), is a
leading cause of fatal pneumonia in HIV-positive persons
and other immunosuppressed patients. Research on P.
jirovecii has been hampered by the lack of a reliable in
vitro culture system, so investigators have developed
molecular techniques to characterize isolates. Studies by
the Centers for Disease Control and Prevention, San
Francisco General Hospital, and other medical centers in
the United States that use these techniques have provided
epidemiologic insights about P. jirovecii patients (2,3).
Reports of P. jirovecii colonization detected by molecular
probes in persons ranging from healthy young children to
adults with chronic lung diseases raise the possibility that
this organism may have medical and public health conse-
quences beyond those on the immunocompromised host
(4,5).
Serologic analysis may be useful in epidemiologic
studies of P. jirovecii infection, especially in light of evi-
dence that antibodies contribute to host defenses against
the organism (6–8). Unfortunately, despite >40 years of
investigation, a useful serologic test for P. jirovecii is not
yet available (9,10). Antigens have mainly consisted of
crude extracts from infected human or rodent lungs. These
preparations have shown that antibodies to the organism
are highly prevalent in the general population (4,11,12) but
have been unable to distinguish present from past infection
or colonization from active disease. Specific native P.
jirovecii antigens have shown more promise as serologic
reagents, but they are in short supply (11,13). This problem
has been exacerbated by data about genetic diversity and
host specificity of Pneumocystis, which have emphasized
the importance of matching organisms used in studies with
the host from which they have been derived (1).
More recent attention has turned toward the use of
recombinant P. jirovecii antigens to study host immune
responses (14–19). The major surface glycoprotein (Msg
or gpA) is highly immunogenic and contains protective B-
and T-cell epitopes, and the heavily glycosylated portion of
the antigen plays a central role in the interaction of the
organism with the host (6–10,20). Msg represents a family
of proteins encoded by multiple genes and is thus capable
of antigenic variation, which may serve as a mechanism to
evade host immune responses. Our strategy has been to use
a single Msg isoform that would enable us to begin to
understand the host immune response to this complex gly-
coprotein. We developed 3 overlapping recombinant
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fragments (MsgA, MsgB, and MsgC), which span the
entire length of the P. jirovecii Msg, and analyzed their
reactivity with serum antibodies in different populations
by Western blot (WB) and ELISA (17,18). A key finding in
both studies was that asymptomatic, HIV-positive patients
in Cincinnati with a past episode of Pneumocystis pneumo-
nia (PCP) had a significantly higher degree of antibody
reactivity to MsgC, the carboxyl terminus and most con-
served part of the antigen, than patients who had never had
the disease.
In this pilot study, we sought to determine whether
serum antibody levels to MsgA, MsgB, and MsgC differed
in HIV-positive patients with acute pneumonia due to P.
jirovecii compared to those with pneumonia due to other
causes. Further, we asked whether serum antibody levels
would rise in these patients during treatment and recovery
from pneumocystosis, which Msg fragment could best
detect this increase, and whether specific host factors were
associated with the antibody rise.
Materials and Methods
Patients and Study Design
As standard clinical practice, HIV-positive patients who
came to San Francisco General Hospital with respiratory
signs and symptoms compatible with pneumocystosis were
evaluated by a uniform protocol that has been described
previously (21). This protocol included obtaining speci-
mens by induced sputum and, if necessary, bronchoscopy
with bronchoalveolar lavage. Microscopic examination and
cultures were used to establish a specific etiologic diagno-
sis. Consecutive patients undergoing sputum induction or
bronchoscopy to diagnose PCP were enrolled in this study
and provided written, informed consent to allow their med-
ical records to be abstracted with a standardized data form.
Study investigators classified patients as either PCP posi-
tive or PCP negative (controls), according to predetermined
definitions that were blinded to serologic results.
Pneumocystis patients were those patients with a micro-
scopically confirmed diagnosis of P. jirovecii; these
patients were treated with standard anti-Pneumocystis
drugs as part of their regular medical care. Control patients
were those whose microscopic examinations were negative
for P. jirovecii, had Pneumocystis treatment discontinued,
and recovered from acute pneumonia.
The study was conducted during a 4.5-year period
(May 2000 through September 2004). During the first half
of the study (2000–2002), an acute-phase serum specimen
was drawn at the time of hospital admission for pneumo-
nia, and a single convalescent-phase specimen was drawn
at different intervals 5–12 weeks later. Preliminary analy-
sis suggested that the Pneumocystis patients experienced a
rise in mean serum antibody levels, whereas controls did
not. Thus, during the later part of the study (2003–2004),
additional serial convalescent-phase serum specimens
were drawn every 1–2 weeks for 6 weeks from patients
with pneumocystosis to measure early changes in antibody
levels. Serum specimens were stored at −70°C and shipped
to the University of Cincinnati for analysis. University of
California San Francisco and University of Cincinnati
institutional review boards approved the protocol.
Analysis of Serum Antibodies
Serum antibody levels to MsgA, MsgB, and MsgC
were measured in a blinded manner by an ELISA as previ-
ously described (14,17,18). All serum specimens and the
standard reference serum were diluted 1:100 and tested in
duplicate wells of a 96-well plate against the following
reagents: recombinant Msg fragments, Escherichia coli
extract expressing the pET vector without insert (vector
control), tetanus toxoid (TT) (positive control), and phos-
phate-buffered saline (PBS) without antigen (negative con-
trol). As an additional negative control, PBS was
substituted for the serum specimen. Plates were washed,
horseradish peroxidase (HRP)–labeled goat anti-human
immunoglobulin G was added, plates were washed again,
and tetramethylbenzidine substrate was added. The reac-
tion was stopped by adding 0.18 mol/L H2SO4, and the
plates were read at a wavelength of 450 nm. The reference
serum specimen, which was obtained from a single person
and had known reactivity to Msg, was run on each day as
another control. HRP-labeled S-protein was used as a pos-
itive control and to correct for antigen loading. During the
early part of the study, patient and reference serum speci-
mens were tested at 1:100, 1:500 and 1:2,500 dilutions.
The best results were obtained with the 1:100 dilution, so
this dilution was used for the remainder of the study. The
reactivity of each serum specimen to Msg was expressed
as the ratio of reactivity to the pET vector: (mean optical
density [OD] Msgtest serum – mean OD PBStest serum) / (mean
OD pETtest serum __ mean OD PBStest serum).
Statistical Analysis
Sex and racial distributions of Pneumocystis patients
and controls were compared by using χ2 tests of equality
of proportions. Means and standard deviations were calcu-
lated to compare the center and spread of age and continu-
ous parameters measured at enrollment (baseline). Mean
values for Pneumocystis patients and controls were com-
pared and tested for equality by using unpaired t tests with
adjustment for unequal variances, either on the original or
logarithmic scale. Geometric means and geometric stan-
dard deviations were calculated when data were approxi-
mately lognormally distributed, as judged by Shapiro-
Wilks tests and visual assessment. Quantile-quantile plots
of serum antibody levels showed that their distributions
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were approximately lognormal, except for larger numbers
of values at the lower quantiles. Pearson product moment
correlations among clinical parameters and Msg fragments
were obtained. Analyses of trends in mean values of each
outcome were performed for all patients enrolled at base-
line during either study period and followed up at least
once at weeks 1–2, 3–4, or 5–6. Sparse data at later follow-
up weeks precluded their inclusion in the regression analy-
ses because of instability of parameter estimates. In
addition, the numbers of patients observed at baseline and
each follow-up time were too small to provide meaningful
inferences from analysis.
Two stratifications of Pneumocystis patients were
investigated with respect to trends and mean levels of Msg
fragments: patients with CD4+ counts above and below
the median value (≈50 cells/µL) and patients with and
without a history of pneumocystosis. The analysis provid-
ed comparisons between means for patient categories at
each follow-up week, as well as differences in patterns of
change over time between patient groups. We obtained p
values that compared mean values between periods and
levels of CD4+ count or history of Pneumocystis pneumo-
nia by using t tests with Tukey’s adjustment for multiple
comparisons. Patient-specific deviations from group
means were included in the analysis as a random effect,
which allowed the correlation between repeated measure-
ments on the same patient over time to be included in
between- and within-patient variance estimates. A p value
<0.05 (2-tailed) was considered significant, unless stated
otherwise. Analyses were performed by using the SAS
procedure PROC MIXED (SAS for Windows version 9.2,
SAS Institute Inc., Cary, NC, USA)
Results
Demographic and Clinical Characteristics
No significant differences were seen between the 80
Pneumocystis patients and the 41 control patients with
other causes of pneumonia in terms of sex, race, or age
(Table 1). Baseline serum albumin levels, arterial blood
gas measurements, and the proportion of patients who
required mechanical ventilation were also similar, which
indicates that the overall general health of patients and the
severity of pneumonia in these 2 groups were also compa-
rable. In addition, the proportion of patients with prior
pneumocystosis was similar in both groups. However, the
Pneumocystis patients had more advanced or more poorly
controlled HIV infection than did the controls. The P.
jirovecii patients had a significantly lower geometric mean
CD4+ count and a significantly higher mean plasma HIV
RNA level than did control patients. Patients with pneumo-
cystosis also exhibited a significantly higher mean serum
lactate dehydrogenase (LDH) level than did controls; this
finding is consistent with the observation that elevated
serum LDH is a nonspecific indicator of PCP.
Baseline and Sequential Serum Antibody 
Levels to MsgC
At the time of hospital admission for pneumonia, geo-
metric mean serum antibody levels to MsgC in
Pneumocystis patients and controls were similar (Table 1).
Forty-one of 80 patients with PCP had >1 convalescent-
phase serum specimen drawn in the first 6 weeks after hos-
pital admission. The total number of patient visits was 62.
Patients observed at weeks 3–4 (n = 19) had a higher mean
serum antibody level to MsgC than the average level of all
patients at baseline (n = 80) and patients observed at weeks
1–2 (n = 25) and weeks 5–6 (n = 18). Differences were sig-
nificant, as determined by t statistics comparing group
means, adjusted for paired comparisons (p<0.01 to
p<0.001) (Table 2). Mean antibody levels at subsequent
time points were 3.7 at 5–6 weeks, 4.0 at 7–8 weeks, and
3.0 at 9–12 weeks (data not shown).
Analysis of serum antibody levels in individual patients
showed different patterns of reactivity (Figure). Eleven
(58%) of the 19 patients studied at 3–4 weeks had an
increase in their antibody levels, ranging from 1.4- to
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22-fold above baseline levels. To determine if the rise in
serum antibodies in the Pneumocystis patients at 3–4
weeks was specific for P. jirovecii or part of a broader
increase in antibody reactivity, we examined the changes
in antibody levels to TT in these 19 patients. The geomet-
ric mean antibody levels of 80 U at baseline and 117 U at
3–4 weeks were not significantly different.
Predictors of Serum Antibody Response to MsgC
among Pneumocystis Patients
We examined clinical characteristics associated with an
increase in antibody levels. No relationship was found
between antibody level and sex, race, age, HIV viral load,
serum albumin level, oxygenation, LDH level, or use of
mechanical ventilation. CD4+ cell count (analyzed as
CD4+ count <50 cells/µL or >50 cells/µL) was significant-
ly associated with the ability to generate an increase in
antibody levels (Table 2). Patients with CD4+ counts <50
cells/µL exhibited no significant changes in antibody lev-
els to MsgC at any time point. In contrast, patients with
CD4+ counts >50 cells/µL had a rise in mean antibody
level, which peaked at 30.4 at 3–4 weeks and which was
significantly higher than antibody levels at baseline
(p<0.001) and at 5–6 weeks (p<0.001). The mean antibody
level at 3–4 weeks in these patients was also significantly
higher than the corresponding level in patients with <50
CD4+ cells (30.4 vs. 6.3, p<0.03).
The lack of a history of pneumocystosis also seemed to
influence antibody response but not baseline antibody
level. The mean antibody level to MsgC in the 59 patients
with first episode of PCP was 4.1; this value was not sig-
nificantly different from the mean value of 4.2 in the 19
patients with recurrent pneumocystosis (Table 3).
Sequential antibody responses were compared in PCP
patients whose episode of pneumonia was their first expe-
rience with the disease versus those whose pneumonia was
a recurrent bout of the disease. Antibody levels in naive
patients increased and reached a peak mean value of 17.9
at 3–4 weeks compared to 4.1 at baseline (p<0.001),
whereas patients with a history of P. jirovecii pneumonia
experienced no increase. Because the number of patients
was low, we could not analyze the combined effects of
PCP history and CD4+ cell count.
Baseline and Sequential Serum Antibody Levels to
MsgA and MsgB
The baseline geometric mean serum antibody level to
MsgA of 5.6 in PCP patients was not significantly differ-
ent from the mean level of 3.7 in the controls (Table 1).
Patients with pneumocystosis exhibited a different pattern
of antibody response to MsgA than to MsgC in that the
mean peak antibody levels to MsgA at 1–2 weeks and 3–4
weeks were similar (Table 4). However, none of the differ-
ences in antibody levels at different time points reached
significance. In addition, no significant differences were
found in the antibody levels at different time points in
patients with and without a history of pneumocystosis or in
patients with CD4+ cell counts <50 cells/µL or patients
with CD4+ counts >50 cells/µL (data not shown).
No significant difference in baseline geometric mean
serum antibody levels to MsgB was seen in patients with
PCP and controls (Table 1). No significant differences
were seen in antibody levels related to different time
points, CD4+ counts, or history of pneumocystosis (data
not shown).
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Figure. Sequential serum antibody responses to major surface gly-
coprotein C (MsgC) in HIV-positive patients with pneumocystosis.
Patients 1 and 2: antibody levels rose from 21.6 and 3.2 at base-
line (point 0) to 55.8 and 23.1 at 3–4 weeks and fell to 36.9 and
4.3, respectively, at 7–8 weeks; patient 3: antibody level showed
few changes from baseline until it rose to 77.1 at 5–6 weeks;
patient 4: antibody level remained at baseline level of 1.0 through-
out.
Discussion
Recombinant antigens derived from P. jirovecii have
begun to attract attention as possible reagents for analyz-
ing antibodies to Pneumocystis in humans (14–19). We
have previously reported that HIV-positive, PCP-positive
patients in Cincinnati had a significantly higher frequency
and level of serum antibodies to MsgC than did HIV-posi-
tive, PCP-negative patients (17,18); this difference was not
found with MsgA or MsgB. These patients were selected
on the basis of a history of pneumocystosis and were clin-
ically healthy. The present pilot study has extended these
observations to HIV-positive patients hospitalized with
acute pneumonia due to P. jirovecii and other causes (con-
trols) in San Francisco. The goal of the first part of this
study was to determine if baseline antibody levels to the 3
Msg fragments in PCP patients differed from those in the
controls. Data showed that the geometric mean antibody
levels to MsgC, MsgA, and MsgB were similar in both
groups.
In the second part of this study, we analyzed the
sequential changes in antibody levels to the 3 Msg frag-
ments in P. jirovecii patients after treatment and recovery
from pneumocystosis. The results showed a significant rise
in mean antibody levels to MsgC that reached a peak at
3–4 weeks. In contrast to MsgC results, no significant
changes in antibody levels to MsgA or MsgB occurred at
any time point. The pattern of antibody reactivity to these
Msg fragments also differed to some degree from the pat-
tern of reactivity to MsgC. Taken together, these data sug-
gest that MsgC is the best Msg fragment to use to analyze
antibody responses in this population of HIV-positive
patients with active Pneumocystis pneumonia.
An antibody rise by 3–4 weeks occurred in 58% of the
Pneumocystis patients we studied. Of the potential host
factors that could affect antibody responses, we were most
interested in CD4+ cells, HIV RNA level, and previous
history of pneumocystosis. Patients with CD4+ cell counts
<50 cells/µL did not mount an antibody response, whereas
patients with CD4+ counts >50 cells/µL that peaked 3–4
weeks after diagnosis showed a vigorous antibody
response. In contrast to CD4+ count, mean viral load in P.
jirovecii patients was not associated with an increase in
antibody levels. Previous reports have shown that CD4+
cells and HIV itself affect antibody responses in HIV-pos-
itive patients, which can be reversed by highly active anti-
retroviral therapy (HAART) (22–24). In HIV-positive
patients who are severely immunocompromised and have
experienced opportunistic infections such as pneumocys-
tosis, however, this immune reconstitution may be incom-
plete (25). Perhaps some who did not respond to treatment
fall into this category, but we did not have information
about HAART use and immune reconstitution in this
cohort.
Our data showed that pneumocystosis patients with or
without a previous episode of the disease had similar base-
line antibody levels to MsgC; however, patients who expe-
rienced their first bout of PCP had better antibody
responses after recovery from the disease. Those who were
experiencing a recurrent bout of pneumocystosis may have
been unable to mount an antibody response to previous
episodes and remained at risk. CD4+ cell count or differ-
ences in the treatment of pneumocystosis might also play
a role in the ability of patients without a previous history
of pneumocystosis to mount an antibody response, but our
analysis was not powered to analyze multiple factors
simultaneously.
Comparison of our results with previous work is com-
plicated by the fact that these earlier studies were per-
formed in the pre-HAART era and involved crude or
native antigens. Analysis of whether a detectable antibody
Antibody Response to Pneumocystis jirovecii
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response to Pneumocystis antigens could develop in HIV-
positive patients who recovered from pneumocystosis pro-
duced conflicting results (9–11,26–30). One report showed
a rise in antibodies to native Msg in 43% of HIV-positive
patients; host factors such as CD4+ count or pO2 could not
distinguish responders from nonresponders (13). A more
recent study that used different recombinant Msg con-
structs than we used found that HIV-negative, immuno-
compromised patients who recovered from pneumo-
cystosis had increased antibody levels, but HIV-positive
patients who recovered had lower levels and poor antibody
responses (16). One factor that may contribute to these dis-
parate results is antigenic variation, which involves differ-
ences in the Msg constructs themselves. We have
developed several variants of our current Msg construct
and found that they differ in their ability to distinguish
among HIV-positive patients who have and not have had
pneumocystosis (unpub. data). PCP patients exhibit greater
reactivity with multiple MsgC clones than do patients
without PCP or blood donors, but whether the antigens that
are recognized are cross-reactive or clone specific is
unclear. Further studies to identify broadly reactive MsgC
antigens associated with recovery from PCP, as well as
proteins (e.g., Kex1) encoded by single-copy genes, would
be of interest (19).
The sequential serologic results reported here, which
were obtained from a limited number of patients, provide
the basis for a large, prospective, multisite study of
sequential antibody responses to MsgC in HIV-positive
patients who have pneumonia caused by P. jirovecii and
other organisms. Serologic surveys need to be performed
in different areas to determine which Msg fragment is the
predominant fragment recognized by HIV-positive patients
and healthy persons. Standardizing Msg antigen prepara-
tions, ELISA conditions, and data analysis would be help-
ful so that serologic results could be reproduced in
different laboratories.
The development of a successful serologic test for
Pneumocystis infection will have clinical and epidemio-
logic applications. Serologic tests with MsgC might be
used in the diagnosis of pneumonia in situations (e.g., in
developing countries) in which a specific cause cannot be
established; in cohort studies to investigate the relationship
of serum antibody levels and the risk for, and recovery
from, Pneumocystis pneumonia; in seroepidemiologic sur-
veys and outbreaks of pneumocystosis; and in investigat-
ing the pathogenic role for P. jirovecii in chronic lung
diseases in which colonization of the organism has been
detected (5).
Support for this study was provided by Department of
Veterans Affairs (K.D., P.W.) and the National Institutes of
Health R03 AI570636 (K.D.), K23 HL072117 (L.H.), K23
HL072837 (A.M.), NIH/NCRR K12 RR01175584-01 (K.C.), and
AACTG.21.Pc, U01 AI25467, R01 AI AI06492, F33 AI06527
(P.W.).
Dr Daly is a senior research associate at the University of
Cincinnati. He joined the university in 1998 and has been study-
ing immune responses to Pneumocystis since then. His research
interests include viral and tumor immunology.
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